natgillin/translations-raw huggingface dataset:
Based on the populationpharmacokinetic (PK) model, the volume of distribution of the central compartment (Vc/F) was estimated to be 212 L. Protein binding was not altered in subjects with mild or moderately impaired renal or hepatic function. 
Na podlagi farmakokinetičnega modela populacije je bil volumen porazdelitve v centralnem prostoru (Vc/F) ocenjen na 212 litrov.
PHARMACEUTICAL FORM AND CONTENTS 30 film-coated tablets 
FARMACEVTSKA OBLIKA filmsko obložena tableta
CABOMETYX 20 mg film-coated tablets CABOMETYX 40 mg film-coated tablets CABOMETYX 60 mg film-coated tablets cabozantinib 
CABOMETYX 20 mg filmsko obložene tablete CABOMETYX 40 mg filmsko obložene tablete CABOMETYX 60 mg filmsko obložene tablete kabozantinib
General disorders and administration site conditions fatigue, mucosal inflammation, asthenia, peripheral oedema 
Splošne težave in spremembe na mestu aplikacije utrujenost, vnetje sluznice, astenija, periferni edem
• Decrease in bile flow from the liver 
• zmanjšanje pretoka žolča iz jeter
Cabozantinib treatment should be discontinued in patients with RPLS. 
Pri bolnikih z RPLS je treba zdravljenje s kabozantinibom prekiniti.
Hepatic encephalopathy 
Jetrna encefalopatija
CABOMETYX 20 mg film-coated tablets CABOMETYX 40 mg film-coated tablets CABOMETYX 60 mg film-coated tablets 
CABOMETYX 20 mg filmsko obložene tablete CABOMETYX 40 mg filmsko obložene tablete CABOMETYX 60 mg filmsko obložene tablete
No dose adjustment is indicated when gastric pH modifying agents (i.e., PPIs, H2 receptor antagonists, and antacids) are co-administered with cabozantinib. 
Pri sočasni uporabi zdravil, ki spreminjajo vrednost pH v želodcu (tj. zaviralci protonske črpalke, antagonisti receptorjev H2 in antacidi), odmerka kabozantiniba ni treba prilagajati.
Each film-coated tablet contains 46.61 mg lactose For the full list of excipients, see section 6.1. 
Ena filmsko obložena tableta vsebuje 46,61 mg laktoze.
Effective methods of contraception should be used by male and female patients and their partners during therapy, and for at least 4 months after completing therapy. 
Med zdravljenjem in še vsaj 4 mesece po koncu zdravljenja morajo tako bolniki in bolnice kot tudi njihovi partnerji uporabljati zanesljiv način kontracepcije.
Use caution when driving or using machines. 
Vpliv na sposobnost upravljanja vozil in strojev Med vožnjo ali uporabo strojev bodite previdni.
Loco-regional transarterial embolisation or chemoinfusion procedures: 44% Radiotherapy prior to cabozantinib treatment: 37% Median duration of sorafenib treatment: 5.32 months 
Postopki loko-regionalne transarterialne embolizacije ali kemoinfuzije: 44 %.
In the treatment-naïve RCC study (CABOSUN), diarrhoea was reported in 73% of cabozantinibtreated patients (57/78);Grade 3-4 events in 10%.. 
V študiji, izvedeni pri predhodno nezdravljenih bolnikih s KLC (CABOSUN), so o driski poročali pri 73 % bolnikov, ki so se zdravili s kabozantinibom (57/78); dogodki 3.-4. stopnje pri 10 % bolnikov.
CYP3A4 inducers and inhibitors Cabozantinib is a CYP3A4 substrate. 
Kabozantinib je substrat za CYP3A4.
• Increase in amylase levels in the blood 
• zvišanje ravni amilaze v krvi
Table 3: Summary of PFS findings by independent radiology review committee in RCC subjects following prior vascular endothelial growth factor (VEGF)-targeted therapy (METEOR) 
Preglednica 3: Povzetek izsledkov PFS po oceni neodvisne radiološke komisije pri osebah s KLC po predhodnem zdravljenju, usmerjenem v vaskularni endotelijski rastni faktor (VEGF) (METEOR)
CABOMETYX 40 mg film-coated tablets are yellow, triangle shaped with no score, and identified with “XL” on one side and “40” on the other side. 
Zdravilo CABOMETYX 40 mg filmsko obložene tablete so rumene, trikotne, brez razdelilne zareze, identificirane z "XL" na eni strani in "40" na drugi strani tablete.
The pharmacokinetics of cabozantinib was not evaluated in patients with severe hepatic impairment. 
Pri bolnikih s hudo okvaro jeter farmakokinetike kabozantiniba niso vrednotili.
How CABOMETYX works 
Kako deluje zdravilo CABOMETYX
Probability of Progression-Free Survival 
Verjetnost preživetja brez napredovanja
No cases of hepatic encephalopathy were reported in the RCC studies (METEOR and CABOSUN). 
V študijah, izvedenih pri bolnikih s KLC (METEOR in CABOSUN), o primerih jetrne encefalopatije niso poročali.
CABOMETYX 60 mg film-coated tablets are yellow, oval shaped with no score, and identified with “XL” on one side and “60” on the other side. 
Zdravilo CABOMETYX 60 mg filmsko obložene tablete so rumene, ovalne, brez razdelilne zareze, identificirane z "XL" na eni strani in "60" na drugi strani tablete.
Dose interruption or reduction, or permanent discontinuation of cabozantinib should be considered in case of persistent or recurrent significant abnormalities (see Table 1). 
Če pomembne nepravilnosti vztrajajo ali se ponavljajo, je treba presoditi o prekinitvi odmerjanja, zmanjšanju odmerka ali trajni ukinitvi zdravljenja s kabozantinibom (glejte preglednico 1).
Cardiac electrophysiology An increase from baseline in corrected QT interval by Fridericia (QTcF) of 10 - 15 ms on Day 29 (but not on Day 1) following initiation of cabozantinib treatment (at a dose of 140 mg qd) was observed in a controlled clinical study in medullary thyroid cancer patients. 
V kontroliranih kliničnih študijah pri bolnikih z medularnim rakom ščitnice so opazili zvišanje od izhodišča pri intervalu QT, popravljenem po Fridericiju (QTcF), za 10-15 ms na 29. dan (vendar ne na
In the study in RCC following prior VEGF-targeted therapy (METEOR), the incidence of severe haemorrhagic events (Grade ≥ 3) was 2.1% (7/331) in cabozantinib-treated RCC patients. 
V študiji, izvedeni pri bolnikih s KLC po predhodnem zdravljenju, usmerjenem v VEGF (METEOR), je pojavnost dogodkov hude krvavitve (≥ 3. stopnje) pri bolnikih s KLC, zdravljenih s kabozantinibom, znašala 2,1 % (7/331).
A high-fat meal moderately increased Cmax and AUC values (41% and 57%, respectively) relative to fasted conditions in healthy volunteers administered a single 140 mg oral cabozantinib dose. 
Obrok z visoko vsebnostjo maščob je pri zdravih prostovoljcih, ki so dobili en peroralni odmerek 140 mg kabozantiniba, zmerno zvišal vrednosti Cmax in AUC (41 % oz. 57 %) v primerjavi s stanjem na tešče.
CABOMETYX 20 mg film-coated tablets 
CABOMETYX 20 mg filmsko obložene tablete
The tablets are yellow round with no score, and debossed with “XL” on one side and “20” on the other side of the tablet. 
Tablete so rumene, okrogle brez razdelilne zareze, z vtisom "XL" na eni strani in "20" na drugi strani tablete.
Wound complications 
Ledvična okvara
HBV], or Other), geographic region (Asia, Other Regions), and presence of extrahepatic spread of disease and/or macrovascular invasion (Yes, No) as stratification factors (per IVRS data) 2 estimated using the Cox proportional-hazard model 3 as assessed by investigator per RECIST 1.1 
1 2-stranski stratificirani log-rank test z etiologijo bolezni (HBV [s HCV ali brez], HCV [brez HBV] ali drugo), geografsko regijo (Azija, druge regije) in prisotnost ekstrahepatične razširitve bolezni in/ali invazije v večje krvne žile (Da, Ne) kot faktorji stratifikacije (na osnovi podatkov IVRS)
Fertility 
sunitinib
• Increase in lipase levels in the blood 
• zvišanje ravni lipaze v krvi
CABOMETYX Placebo these therapies had to discontinue study treatment. 
Bolniki, ki so bili deležni teh oblik zdravljenja, so morali zdravljenje v študiji prekiniti.
Method of administration CABOMETYX is for oral use. 
Zdravilo CABOMETYX se jemlje peroralno.
CABOMETYX 20 mg film-coated tablets Each film-coated tablet contains cabozantinib (S)-malate equivalent to 20 mg cabozantinib. 
CABOMETYX 20 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje kabozantinib (S)-malat, kar ustreza 20 mg kabozantiniba.
CABOMETYX 60 mg film-coated tablets 
CABOMETYX 60 mg filmsko obložene tablete
In the treatment-naïve RCC study (CABOSUN), the incidence of severe haemorrhagic events (Grade ≥ 3) was 5.1% (4/78) in cabozantinib-treated RCC patients. 
V študiji, izvedeni pri predhodno nezdravljenih bolnikih s KLC (CABOSUN), je pojavnost dogodkov hude krvavitve (≥ 3. stopnje) pri bolnikih s KLC, ki so se zdravili s kabozantinibom, znašala 5,1 %
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER NAME OF THE MEDICINAL PRODUCT CABOMETYX 20 mg film-coated tablets cabozantinib NAME OF THE MARKETING AUTHORISATION HOLDER Ipsen Pharma EXPIRY DATE 
IME ZDRAVILA CABOMETYX 20 mg filmsko obložene tablete kabozantinib IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Ipsen Pharma DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
What you need to know before you take CABOMETYX Do not take CABOMETYX 
Kaj je zdravilo CABOMETYX in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo CABOMETYX Kako jemati zdravilo CABOMETYX Možni neželeni učinki
What CABOMETYX is 
Kaj je zdravilo CABOMETYX
• Shortness of breath 
• vnetje trebušne slinavke
CABOMETYX 40 mg film-coated tablets 
CABOMETYX 40 mg filmsko obložene tablete
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER NAME OF THE MEDICINAL PRODUCT CABOMETYX 60 mg film-coated tablets cabozantinib NAME OF THE MARKETING AUTHORISATION HOLDER Ipsen Pharma EXPIRY DATE 
IME ZDRAVILA CABOMETYX 60 mg filmsko obložene tablete kabozantinib IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Ipsen Pharma DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER NAME OF THE MEDICINAL PRODUCT CABOMETYX 40 mg film-coated tablets cabozantinib NAME OF THE MARKETING AUTHORISATION HOLDER Ipsen Pharma EXPIRY DATE 
IME ZDRAVILA CABOMETYX 40 mg filmsko obložene tablete kabozantinib IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Ipsen Pharma DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Ear and labyrinth disorders tinnitus 
Ušesne bolezni, vključno z motnjami labirinta tinitus
PFS and ORR findings are summarized in Table 6. 
Povzetek rezultatov za preživetje brez napredovanja bolezni (PFS) in delež objektivnega odziva (ORR) je prikazan v preglednici 6.
The tablets are yellow oval shaped with no score, and debossed with “XL” on one side and “60” on the other side of the tablet. 
Tablete so rumene, ovalne brez razdelilne zareze, z vtisom "XL" na eni strani in "60" na drugi strani tablete.
The tablets are yellow triangle shaped with no score, and debossed with “XL” on one side and “40” on the other side of the tablet. 
Tablete so rumene, trikotne brez razdelilne zareze, z vtisom "XL" na eni strani in "40" na drugi strani tablete.
NAME OF THE MEDICINAL PRODUCT CABOMETYX 20 mg film-coated tablets cabozantinib STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains cabozantinib (S)-malate equivalent to 20 mg of cabozantinib. 
IME ZDRAVILA CABOMETYX 20 mg filmsko obložene tablete kabozantinib NAVEDBA ENE ALI VEČ UČINKOVIN Ena tableta vsebuje kabozantinib (S)-malat, kar ustreza 20 mg kabozantiniba.
CABOMETYX 60 mg film-coated tablets: Each tablet contains cabozantinib (S)-malate equivalent to 60 mg of cabozantinib. 
CABOMETYX 60 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje kabozantinib (S)-malat, kar ustreza 60 mg kabozantiniba.
In the HCC study (CELESTIAL), hepatic encephalopathy was reported more frequently in the cabozantinib than the placebo arm. Cabozantinib has been associated with diarrhoea, vomiting, decreased appetite and electrolyte abnormalities. 
V študiji HCK (CELESTIAL) so o jetrni encefalopatiji poročali pogosteje v skupini s kabozantinibom kot v skupini s placebom.
Fatal perforations have occurred in the cabozantinib clinical program. 
V kliničnem programu kabozantiniba so se pojavile perforacije, ki so se končale s smrtjo bolnika.
(see section 2 for lactose content) - Film coating: hypromellose, titanium dioxide (E171), triacetin, iron oxide yellow (E172) What CABOMETYX looks like and contents of the pack CABOMETYX 20 mg film-coated tablets are yellow, round with no score, and identified with “XL” on one side and “20” on the other side. 
Izgled zdravila CABOMETYX in vsebina pakiranja Zdravilo CABOMETYX 20 mg filmsko obložene tablete so rumene, okrogle, brez razdelilne zareze, identificirane z "XL" na eni strani in "20" na drugi strani tablete.
Progression-free survival (PFS) by Investigator Median PFS in months (95% CI) HR (95% CI); stratified b,c Two-sided log-rank p-value: stratified b p=0.0042 
Preživetje brez napredovanja bolezni (PFS) po oceni raziskovalca Mediana PFS v mesecih (95-% IZ) HR (95-% IZ); stratificiranib,c
CABOMETYX 40 mg film-coated tablets: Each tablet contains cabozantinib (S)-malate equivalent to 40 mg of cabozantinib. 
CABOMETYX 40 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje kabozantinib (S)-malat, kar ustreza 40 mg kabozantiniba.
A population PK analysis did not identify clinically relevant differences in PK of cabozantinib based on race. 
Podatki, na podlagi katerih bi bilo mogoče ugotoviti razlike v farmakokinetiki na podlagi rase, niso na voljo.
Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. 
Pri bolnikih s KLC in HCK je priporočeni odmerek zdravila CABOMETYX 60 mg enkrat na dan. Zdravljenje je treba nadaljevati tako dolgo, dokler bolnik več nima kliničnih koristi od terapije ali do pojava nesprejemljive toksičnosti.
• Wound complications 
• zapleti z ranami
• Increase in level of potassium in the blood 
• zvišanje ravni kalija v krvi
• Swelling, pain in your hands and feet, or shortness of breath. 
• oteklina, bolečina dlani ali stopal ali kratka sapa
ORR (partial responses only) Stable disease 
ORR (le delni odzivi)
Progression-free survival (PFS) by IRC a Median PFS in months (95% CI) HR (95% CI); stratified b,c Two-sided log-rank p-value: stratified b p=0.0005 
Preživetje brez napredovanja bolezni (PFS) po oceni IRC a Mediana PFS v mesecih (95-% IZ) HR (95-% IZ); stratificiranib,c
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON NAME OF THE MEDICINAL PRODUCT CABOMETYX 40 mg film-coated tablets cabozantinib STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains cabozantinib (S)-malate equivalent to 40 mg of cabozantinib. 
IME ZDRAVILA CABOMETYX 40 mg filmsko obložene tablete kabozantinib NAVEDBA ENE ALI VEČ UČINKOVIN Ena tableta vsebuje kabozantinib (S)-malat, kar ustreza 40 mg kabozantiniba.
Severe haemorrhage, sometimes fatal, has been observed with cabozantinib. 
Pri uporabi kabozantiniba so opazili hude krvavitve, ki so bile včasih tudi usodne.
Fatal haemorrhages have occurred in the cabozantinib clinical program. 
V kliničnem programu kabozantiniba so se pojavile krvavitve, ki so se končale s smrtjo bolnika.
Each film-coated tablet contains cabozantinib (S)-malate equivalent to 60 mg cabozantinib. 
Zdravilo CABOMETYX 60 mg filmsko obložene tablete vsebuje kabozantinib (S)-malat, ki ustreza 60 mg kabozantiniba.
Avoid becoming pregnant while being treated with CABOMETYX. 
Med uporabo zdravila CABOMETYX ne smete zanositi.
Each film-coated tablet contains cabozantinib (S)-malate equivalent to 40 mg cabozantinib. 
Zdravilo CABOMETYX 40 mg filmsko obložene tablete vsebuje kabozantinib (S)-malat, ki ustreza 40 mg kabozantiniba.
• Bone damage in the jaw 
• okvara čeljustne kosti
Therefore, the recommendations made here can only be used as a starting point for individual dose setting. 
Zato se tukaj navedena priporočila uporablja le kot izhodišče za določitev posameznega odmerka.
{Name and address} <{Tel}> <{Fax}> <{E-mail}> 
{Ime in naslov} <{tel}> <{faks}> <{e-pošta}>
The main areas of disharmony in the existing product information relate to: 
Glavna področja razhajanja v obstoječih informacijah o zdravilu se nanašajo na:
aureus, together with a bacteriological cure of 66.67%. 
aureus, bakteriološko ozdravitev pa pri 66,67 %.
Reptiles are ectothermic, relying on external heat sources to maintain their body temperature at the optimum level for correct function of all body systems. 
Plazilci so ektotermični , odvisni od zunanjih virov toplote , da ohranijo svojo telesno temperaturo na optimalni ravni, za pravilno delovanje vseh telesnih sistemov.
These signs are generally mild and transient. 
Ti znaki so navadno blagi in prehodni.
Do not eat, drink or smoke whilst handling the product. 
Med dajanjem pripravka, ne jejte, pijte ali kadite.
Litvínovská 609/3 190 21 Praha 9 
Litvínovská 609/3 190 21 Praha 9 Češka
Because the safety and the efficiency of the product have not been assessed in cats less than 8 weeks, the contraindication in such animals is justified. 
Ker varnosti in učinkovitosti zdravila niso ocenili pri mačkah, mlajših od 8 tednov, je kontraindikacija pri teh živalih upravičena.
Bayer Hungária Kft. Alkotás u. 50 
Madžarska Bayer Hungária Kft. Alkotás u. 50
No residue depletion data were made available. 
Podatki o izločanju ostankov niso na voljo.
Do not use in cats less than 8 weeks of age. 
Ne uporabite pri mačkah, mlajših od 8 tednov starosti.
Therefore, the veterinarian must be aware of the correct temperature requirements of the respective reptile species and the hydration status of the individual patient. 
Zato mora veterinar poznati ustrezne temperaturne zahteve določenih vrst plazilcev in status hidracije posameznega pacienta.
If necessary, depending on the severity of clinical signs, this dosage can be doubled. 
Po potrebi, dovisno od teže kliničnih znakov odmerek lahko podvojimo.
Do not use in growing horses because of possible deleterious damage on articular cartilage. 
Ne uporabite pri rastočih konjih, zaradi možnih poškodb sklepnega hrustanca.
Do not use concurrently with theophylline as the elimination of theophylline may be delayed. 
Ne uporabljajte sočasno s teofilini, ker se izločanje teofilina lahko upočasni.
The overall benefit-risk balance of the products was deemed positive subject to the recommended changes in the product information (see Annex III). 
Celotno razmerje med tveganji in koristmi za zdravila je bilo ocenjeno kot ugodno pod pogojem, da se upoštevajo priporočene spremembe v informacijah o zdravilu (glejte Prilogo III).
Wash any splashes from skin or eyes immediately with water. 
Pri stiku pripravka s kožo ali očmi, kožo in oči nemudoma sperite z vodo.
In countries where feeding of fallen stock to scavenger bird populations is permitted as a conservation measure (see Commission Decision 2003/322/EC), the possible risk to hatching success should be considered before feeding carcasses of livestock recently treated with this product. 
V državah, kjer je krmljenje poginulih živali pticam mrhovinarkam dovoljeno kot ukrep za ohranjanje vrst (glej Sklep Komisije 2003/322/ES), je treba upoštevati možno tveganje za valjenje, pred hranjenjem s kadavri živine, ki je bila pred kratkim zdravljena s tem zdravilom.
The success rate was 76% on day 3 and 50% on day 10 in the test group versus 14.3% and 9.5%, respectively, for the same days, for the reference product. 
Delež uspešnosti v preiskovani skupini je bil 76-odstoten na 3. dan in 50odstoten na 10. dan v primerjavi s 14,3- oziroma 9,5-odstotnim deležem na ista dneva pri referenčnem zdravilu.
An extension of the treatment interval to 48 hours may be necessary in individual cases. 
Včasih je pri posameznih primerih potrebno podaljšanje intervala zdravljenja do 48 ur.
In very rare cases intravenous treatment of cattle can cause shock reactions, presumably as a result of circulatory impairment. 
V redkih primerih lahko intravenozno zdravljenje goveda povzroči šok reakcije, domnevno kot posledica oslabitve obtočil.
During this referral and considering the scope of the procedure, adequate data have been submitted to support the following posology (depending on the indications): 
Glede na obseg postopka je bilo med tem napotitvenim postopkom predloženih dovolj podatkov, ki so podprli naslednje odmerjanje (odvisno od indikacij):
In dogs, a moderate and transient local reaction (such as oedema) may occur. 
Pri psih se lahko pojavijo zmerne in prehodne lokalne reakcije (kot je oteklina).
In accidental overdose there is no antidote and treatment should be symptomatic. 
V primeru nenamerne aplikacije prevelikega odmerjanja ni antidota, zdravljenje pa mora biti simptomatsko.
However, the provided results do not allow assessing the efficacy of the products for each one of these agents individually because only data about M. haemolytica have been provided. 
Vendar pa predloženi rezultati niso omogočili ocene učinkovitosti zdravil za posamezne povzročitelje, saj so bili predloženi samo podatki za M. haemolytica.
The local tolerance was followed during tolerance and/or clinical studies in pigs, calves and dogs. 
Lokalno toleranco so proučevali v študijah tolerance in/ali kliničnih študijah na prašičih, teletih in psih.
Detrimental effects on developing eggs of avian scavengers were reported when these birds ingest livestock meat from animals previously administered with fluoroquinolone. 
Poročali so o škodljivih učinkih na razvijajoča se jajca ptičev mrhovinarjev, kadar te ptice zaužijejo meso živine, ki je predhodno prejemala fluorokinolon.
The presence of the renal portal system in reptiles means it is prudent to administer substances in the front half of the body wherever possible. 
Prisotnost portalnega sistema ledvic plazilcev zahteva dajanje snovi v prvo polovico telesa, kjer je to mogoče .
Although horses are not authorised as target species the Committee considered that a contraindication for use in growing horses should be included in the product information for the 50 mg/ml and 100 mg/ml strengths. 
Čeprav konji niso odobrena ciljna živalska vrsta, je odbor menil, da mora biti kontraindikacija za uporabo pri odraščajočih konjih vključena v informacije o zdravilu, in sicer za jakosti 50 mg/ml in 100 mg/ml.
In case of complicated infections higher doses may be necessary. 
V primeru zapletenih okužb so lahko potrebni večji odmerki.
Metabolism of substances and activity of the immune system are, thus, critically dependent on the body temperature. 
Presnova snovi in aktivnosti imunskega sistema so močno odvisni od telesne temperature .
Mild and transient digestive tract disorders are common with many antibiotics, including fluoroquinolones. 
Blage in prehodne prebavne motnje so pogoste pri mnogih antibiotikih, vključno s fluorokinoloni.
Then in countries where feeding of fallen stock to scavenger bird populations is permitted as a conservation measure special warnings have to be keep in order to reduce the risk for these birds. 
V državah, kjer je hranjenje populacij ptičev mrhovinarjev s poginulo živino dovoljeno kot ohranitveni ukrep, je treba uvesti in vzdrževati posebna opozorila, da se zmanjša tveganje za te ptice.
Concerning target species cattle and pigs a risk has been identified regarding an insufficient dose rate against target pathogens in cattle and pigs. 
Pri ciljnih živalskih vrstah, govedu in prašičih, so ugotovili tveganje glede nezadostnega odmerjanja proti ciljnim patogenom pri govedu in prašičih.
Overall drug concentrations peak at 2 hours after treatment showing an approximately 3-fold higher total exposure over the 24 hours dosing interval compared to plasma. 
2 urah po zdravljenju, kar kaže na približno 3-krat večjo skupno izpostavljenost v 24 urah intervalnega odmerjanja v primerjavi s plazmo.
In complicated infections, higher dosages and longer treatment courses may be necessary. 
Pri zapletenih okužbah so lahko potrebni višji odmerki in daljše zdravljenje.
Care should be taken to avoid accidental self-injection. 
Previdnost je potrebna, da ne pride do nenamernega samo-injiciranja.
The section on interactions takes into account for all relevant interactions between enrofloxacin and other substances. 
Poglavje o medsebojnem delovanju vključuje vse pomembne interakcije med enrofloksacinom in drugimi učinkovinami.
Do not use in young dogs during their growth, i.e. in small breeds of dogs less than 8 months of age, in big breeds of dogs less than 12 months of age, in giant breeds of dogs less than 18 months of age. 
Ne uporabite pri mladih rastočih psih, to je pri malih pasmah psov do 8. meseca starosti, pri velikih pasmah psov do 12. meseca starosti, pri zelo velikih pasmah psov pa do 18. meseca starosti.
If accidental self-injection occurs seek medical advice immediately. 
V primeru nenamernega samoinjiciranja se takoj posvetujte z zdravnikom.